PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1749645
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1749645
Congestive Heart Failure Treatment Devices Market Growth, Size, Trends Analysis - By Product - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Congestive Heart Failure Treatment Devices Market Introduction and Overview
According to SPER market research, 'Global Congestive Heart Failure Treatment Devices Market Size- By Product - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Congestive Heart Failure Treatment Devices Market is predicted to reach 11 billion by 2034 with a CAGR of 6.98%.
Congestive heart failure treatment devices are medical devices for congestive heart failure (CHF), a condition in which the heart finds it difficult to pump blood efficiently, are made to strengthen heart function and enhance circulation in individuals with CHF. These devices, which improve cardiac output and help control heart rhythms, include pacemakers, ventricular assist devices (VADs), implanted Cardioverter defibrillators (ICDs), and cardiac resynchronization treatment (CRT) devices. Furthermore, remote monitoring devices help identify worsening symptoms early.
Restraints: The market for congestive heart failure (CHF) therapy devices is confronted with various obstacles. Particularly in poor nations, the high expense of implanted devices such as cardiac resynchronization treatment (CRT) and left ventricular assist devices (LVADs) restricts accessibility. Long clinical trials and stringent regulatory permissions cause delays in product introductions. Patients are also at serious risk from device-related problems such thrombosis, infections, and mechanical failures. Market expansion is further hampered by low-income populations' lack of awareness and cost.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Koninkilijke Philips N.V., Lepu Medical Technology Co. Ltd., LivaNova PLC, MEDICO S.p.A., Medtronic plc, MicroPort Scientific Corporation, OSCOR Inc.
Global Congestive Heart Failure Treatment Devices Market Segmentation:
By Product: Based on the Product, Global Congestive Heart Failure Treatment Devices Market is segmented as; Ventricular assist devices, Counter Pulsation Devices, Implantable Cardioverter Defibrillators, Pacemakers, Cardiac Resynchronization therapy.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Table of Contents
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER's internal database
2.1.4. Premium insight from KOL's
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER's Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Congestive Heart Failure Treatment Devices Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Congestive Heart Failure Treatment Devices Market
7. Global Congestive Heart Failure Treatment Devices Market, By Product 2021-2034 (USD Million)
7.1. Ventricular assist devices
7.1.1. LVAD
7.1.2. RVAD
7.1.3. BiVAD
7.2. Counter Pulsation Devices
7.3. Implantable Cardioverter Defibrillators
7.3.1. Transvenous ICDs
7.3.2. Subcutaneous ICDs
7.4. Pacemakers
7.4.1. Implantable
7.4.2. External
7.5. Cardiac Resynchronization therapy
7.5.1. Cardiac Resynchronization Therapy-Defibrillators (CRT-D)
7.5.2. Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
8. Global Congestive Heart Failure Treatment Devices Market, 2021-2034 (USD Million)
8.1. Global Congestive Heart Failure Treatment Devices Market Size and Market Share
9. Global Congestive Heart Failure Treatment Devices Market, By Region, 2021-2034 (USD Million)
9.1. Asia-Pacific
9.1.1. Australia
9.1.2. China
9.1.3. India
9.1.4. Japan
9.1.5. South Korea
9.1.6. Rest of Asia-Pacific
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. United Kingdom
9.2.6. Rest of Europe
9.3. Middle East and Africa
9.3.1. Kingdom of Saudi Arabia
9.3.2. United Arab Emirates
9.3.3. Qatar
9.3.4. South Africa
9.3.5. Egypt
9.3.6. Morocco
9.3.7. Nigeria
9.3.8. Rest of Middle-East and Africa
9.4. North America
9.4.1. Canada
9.4.2. Mexico
9.4.3. United States
9.5. Latin America
9.5.1. Argentina
9.5.2. Brazil
9.5.3. Rest of Latin America
10. Company Profile
10.1. Abbott Laboratories
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Biotronik SE & Co. KG
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Boston Scientific Corporation
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Koninkilijke Philips N.V.
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Lepu Medical Technology Co. Ltd.
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. LivaNova PLC
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. MEDICO S.p.A.
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Medtronic plc
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. MicroPort Scientific Corporation
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. OSCOR Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
11.11. Others
11. Conclusion
12. List of Abbreviations
13. Reference Links
